BioinvestGPT | Data-Free Virtual Clinical Trials with

Sort By

Show 3 Selected Trials

Rows per page

Page 1 of 1

	Clinical Trial	Certified Prospective Prediction	Prediction Validation	Prediction Result
Phase 3	Prediction Index2094 NCTIDNCT06081894 Drug NameAficamten Drug MoACardiac myosin inhibitor Drug Modalitysmall molecule Drug ClassFirst-In-Class Therapeutic AreaCardiovascular Diseases IndicationSymptomatic Non-Obstructive Hypertrophic Cardiomyopathy (non-obstructive HCM) Human Patients500 SponsorCytokinetics TickerCYTK	Prediction Date 16 Nov 2025 Technical PredictionSUCCESS (statistically significant clinical benefit in KCCQ CSS compared with placebo) Commercial Predictionpartial SUCCESS (commercially maybe sufficient yet moderate clinical benefit in KCCQ CSS numerically-to-slightly superior to metoprolol) Timestamped PDFTimestamped PDF Delivered to Clients Quarter AheadQ1'26 Batch 6	Readout Date 4 May 2026 Prediction To Readout169 days in advance Readout Data Interpretationaficamten achieved statistically significant 3.0 placebo-adjusted improvement in KCCQ-CSS (p= 0.021) and 0.67 placebo-adjusted improvement in pVO2 (p= 0.003), moderately superior mavacamten as prospectively predicated in No.1959 (see add'l link below); safe and well-tolerated Press ReleasePress Release Additional Readout DataAdd'l Clinical Benefit Comparison Data	Prediction AccuracyCorrect Prediction Clinical Benefit Conclusionstatistically significant and commercially sufficient (moderately superior to mavacamten) Prediction ClassificationTrue Positive (TP)
Phase 3	Prediction Index1959 NCTIDNCT05582395 Drug NameMavacamten Drug MoAcardiac myosin inhibitor Drug Modalitysmall molecule Drug ClassFirst-In-Class Therapeutic AreaCardiovascular Diseases Indicationnon-obstructive hypertrophic cardiomyopathy (nHCM) Human Patients580 SponsorBristol-Myers Squibb TickerBMY	Prediction Date 2 Apr 2025 Technical Predictionpartial SUCCESS (statistically maybe significant yet weak clinical benefit in KCCQ compared with placebo) Commercial Predictionpartial SUCCESS (commercially maybe sufficient yet weak clinical benefit in KCCQ moderately inferior to aficamten) Timestamped PDFTimestamped PDF Delivered to Clients Quarter Ahead Q2'25 Batch 14b	Readout Date 14 Apr 2025 Prediction To Readout12 days in advance Readout Data Interpretationmavacamten failed to meet either the KCCQ-23 CSS or the pVO2 primary endpoints Press ReleasePress Release	Prediction AccuracyCorrect Prediction Clinical Benefit Conclusionstatistically insignificant and commercially insufficient Prediction ClassificationTrue Negative (TN)
Phase 3	Prediction Index984 NCTIDNCT02831959 Drug NameNovoTTF-200M device Best Standard of Care Drug MoAa device delivering low-intensity; wave-like alternating electric fields to the location of the tumor Drug Modalitymedical device Drug ClassFirst-In-Class Therapeutic AreaNeoplasms IndicationBrain Metastases From Non-small Cell Lung Cancer (NSCLC) Human Patients270 SponsorNovoCure TickerNVCR	Prediction Date 22 Dec 2023 Technical Predictionpartial SUCCESS (statistically significant yet weak additive clinical benefit) Commercial PredictionFAILURE (commercially insufficient additive clinical benefit) Timestamped PDFTimestamped PDF Delivered to Clients Quarter AheadQ1'24 Batch 12	Readout Date 27 Mar 2024 Prediction To Readout96 days in advance Readout Data Interpretation21.9month vs 11.3month time to intracranial progression (p=0.016) OS secondary endpoint not met. Press ReleasePress Release	Prediction AccuracyCorrect Prediction Clinical Benefit Conclusionstatistically significant yet commercially insufficient (no OS benefit) Prediction ClassificationTrue Negative (TN)

Clinical Trial

Certified Prospective Prediction

Prediction Validation

Prediction Result

Phase 3

Prediction Index2094

NCTIDNCT06081894

Drug NameAficamten

Drug MoACardiac myosin inhibitor

Drug Modalitysmall molecule

Drug ClassFirst-In-Class

Therapeutic AreaCardiovascular Diseases

IndicationSymptomatic Non-Obstructive Hypertrophic Cardiomyopathy (non-obstructive HCM)

Human Patients500

SponsorCytokinetics

TickerCYTK

Prediction Date 16 Nov 2025

Technical PredictionSUCCESS (statistically significant clinical benefit in KCCQ CSS compared with placebo)

Commercial Predictionpartial SUCCESS (commercially maybe sufficient yet moderate clinical benefit in KCCQ CSS numerically-to-slightly superior to metoprolol)

Timestamped PDFTimestamped PDF

Delivered to Clients Quarter AheadQ1'26 Batch 6

Readout Date 4 May 2026

Prediction To Readout169 days in advance

Readout Data Interpretationaficamten achieved statistically significant 3.0 placebo-adjusted improvement in KCCQ-CSS (p= 0.021) and 0.67 placebo-adjusted improvement in pVO2 (p= 0.003), moderately superior mavacamten as prospectively predicated in No.1959 (see add'l link below); safe and well-tolerated

Press ReleasePress Release

Additional Readout DataAdd'l Clinical Benefit Comparison Data

Prediction AccuracyCorrect Prediction

Clinical Benefit Conclusionstatistically significant and commercially sufficient (moderately superior to mavacamten)

Prediction ClassificationTrue Positive (TP)

Phase 3

Prediction Index1959

NCTIDNCT05582395

Drug NameMavacamten

Drug MoAcardiac myosin inhibitor

Drug Modalitysmall molecule

Drug ClassFirst-In-Class

Therapeutic AreaCardiovascular Diseases

Indicationnon-obstructive hypertrophic cardiomyopathy (nHCM)

Human Patients580

SponsorBristol-Myers Squibb

TickerBMY

Prediction Date 2 Apr 2025

Technical Predictionpartial SUCCESS (statistically maybe significant yet weak clinical benefit in KCCQ compared with placebo)

Commercial Predictionpartial SUCCESS (commercially maybe sufficient yet weak clinical benefit in KCCQ moderately inferior to aficamten)

Timestamped PDFTimestamped PDF

Delivered to Clients Quarter Ahead Q2'25 Batch 14b

Readout Date 14 Apr 2025

Prediction To Readout12 days in advance

Readout Data Interpretationmavacamten failed to meet either the KCCQ-23 CSS or the pVO2 primary endpoints

Press ReleasePress Release

Prediction AccuracyCorrect Prediction

Clinical Benefit Conclusionstatistically insignificant and commercially insufficient

Prediction ClassificationTrue Negative (TN)

Phase 3

Prediction Index984

NCTIDNCT02831959

Drug NameNovoTTF-200M device Best Standard of Care

Drug MoAa device delivering low-intensity; wave-like alternating electric fields to the location of the tumor

Drug Modalitymedical device

Drug ClassFirst-In-Class

Therapeutic AreaNeoplasms

IndicationBrain Metastases From Non-small Cell Lung Cancer (NSCLC)

Human Patients270

SponsorNovoCure

TickerNVCR

Prediction Date 22 Dec 2023

Technical Predictionpartial SUCCESS (statistically significant yet weak additive clinical benefit)

Commercial PredictionFAILURE (commercially insufficient additive clinical benefit)

Timestamped PDFTimestamped PDF

Delivered to Clients Quarter AheadQ1'24 Batch 12

Readout Date 27 Mar 2024

Prediction To Readout96 days in advance

Readout Data Interpretation21.9month vs 11.3month time to intracranial progression (p=0.016) OS secondary endpoint not met.

Press ReleasePress Release

Prediction AccuracyCorrect Prediction

Clinical Benefit Conclusionstatistically significant yet commercially insufficient (no OS benefit)

Prediction ClassificationTrue Negative (TN)

96%

96%

The Performance Intelligence Suite

Top 50 Pharma

Drug Class

Therapeutic Area

Drug Modality

Phase of Development

Prediction Status

The Performance Intelligence Suite

Top 50 Pharma

Drug Class

Therapeutic Area

Drug Modality

Phase of Development

Prediction Status